Catalyst Wire Dossier Catalyst Wire Dossier

Ilumetri

tildrakizumab · Almirall, S.A.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ilumetri, covering 2025-07-16 to 2025-07-16. Get the full timeline:

Most recent: EMA Authorised: Ilumetri (tildrakizumab) — Almirall, S.A.

See pricing